EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Esprit Pharma, Inc. announced today that it has exercised its option to acquire the marketing rights of the recently approved SANCTURA(R) XR (trospium chloride extended release capsules). Today, Esprit Pharma paid the milestone due upon approval by the U.S. Food and Drug Administration (FDA) to its development and co-promotion partner, Indevus Pharmaceuticals, Inc., securing Esprit rights to market SANCTURA XR in the United States and its territories. Indevus announced on Monday, August 6, that SANCTURA XR had been approved by the FDA.
